All News

Found 82 articles

• Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023

  5/4/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at three upcoming scientific conferences to be held in May 2023.

• Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

  5/1/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) has presented the foundational preclinical data that supported the initial clinical development of its novel serotonin-dopamine stabilizer brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) in San Diego.

• Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

  4/25/2023

  Reviva Pharmaceuticals Holdings, Inc. today announced it will host a KOL webinar on brilaroxazine (RP5063), a serotonin-dopamine modulator in late-stage development for schizophrenia, on May 2 nd at 11:00am ET.

• Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

  4/20/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.

• Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights

  3/30/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today reported financial results for the full year ended December 31, 2022 and summarized recent business highlights.

• Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

  3/7/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 35th Annual Roth Conference, taking place March 12-14 in Dana Point, CA.

• Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference

  1/31/2023

  Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the BIO CEO and Investor Conference being held February 6–9, 2023.

• Reviva Pharmaceuticals Announces Letter to Shareholders

  1/4/2023

  Reviva Pharmaceuticals Holdings, Inc. is pleased to announce a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows.

• Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine

  12/15/2022

  Reviva Pharmaceuticals Holdings, Inc. today announced positive data from its recently completed clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects.

• Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208

  11/21/2022

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced the issuance of a patent covering composition of matter for RP1208 in Canada, adding to its existing protection in key markets around the world. The Canadian patent covers the compositions of novel phenylcycloalkylmethylamine derivatives and the use of the compositions for the treatment of obesity, and related co-morbid conditions and depression and related co-morbid conditions.

• Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

  11/14/2022

  Reviva Pharmaceuticals Holdings, Inc. reported financial results for the third quarter ended September 30, 2022 and summarized recent business highlights.

• Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

  10/31/2022

  Reviva Pharmaceuticals Holdings, Inc. today announced over 30% enrollment in the United States, and initiation and ongoing enrollment across sites in Europe for the pivotal Phase 3 RECOVER study evaluating brilaroxazine for the treatment of schizophrenia.

• 

  Movers & Shakers: CEO Shakeups at BIO, Passage Bio and Palisade Bio

  10/14/2022

  The Biotechnology Innovation Organization, Passage Bio and Palisade Bio saw leadership shakeups at the top, while Maze Therapeutics, Cerecin and more appointed new chief medical officers. 

• Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference

  9/26/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Lytham Partners Fall 2022 Investor Conference being held September 28–29, 2022 and invites investors to participate via virtual one-on-one meetings.

• Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held September 12–14, 2022 and invites investors to participate via virtual one-on-one meetings or in-person in New York, NY.

• Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

  8/15/2022

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2022 and summarized recent business highlights.

• Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

  7/27/2022

  Reviva Pharmaceuticals Holdings is pleased to provide an update on key milestones related to its clinical development pipeline.

• Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention

  6/2/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the 2022 BIO International Convention, to be held June 13-16 in San Diego, CA.

• India In-Vitro Fertilization (IVF) Services Market to Garner Growth 16.45% by 2030

  6/2/2022

  The India IVF services market size was valued at $793.27 Million in 2020 and is projected to reach $3,721.99 Million by 2030 registering a CAGR of 16.45% from 2021 to 2030.

• Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings or in-person in Miami, FL. Please see additional details below.